Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia

By Natalie GoodridgeJune 6, 2017October 29th, 2024Healthcare

No Comments

Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia

https://journals.sagepub.com/doi/pdf/10.1177/1526602817719283

Tags:

LimFlow Healthcare

PreviousLimFlow Expands Senior Management Team and Opens Silicon Valley Office
NextLimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact

Copyright © 2025 M&L Group. All Rights Reserved. | Legal.

Branding and website design by Stepworks